StockGuru Leader Board: MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) Closed Up 10.55% on Thursday

MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) is on The StockGuru Leader Board today.  The stock closed up 10.55% on Thursday.

Volume was 1,402,434 shares traded.

Join in on the Discussion about MAPP

About the Company:

MAP Pharmaceuticals, Inc., a development stage company, focuses on the development and commercialization of drugs in the field of neurology using its inhalation technologies. Its principal product includes LEVADEX, an orally inhaled version of dihydroergotamine mesylate (DHE) that has completed Phase 3 clinical development stage for the acute treatment of migraine. The company’s proprietary technologies consist of particle creation and formulation technologies, which can be applied to small or large molecules, including peptides and proteins. Its technologies also include the development and manufacturing of aerosol delivery platforms, such as TEMPO inhaler, a pressurized metered dose inhaler (MDI) that dispenses drug automatically when the patient inhales. MAP Pharmaceuticals, Inc. has a collaboration and co-promotion agreement with Allergan, Inc. to market and promote LEVADEX to neurologists and pain specialists in the United States; a license agreement with Nektar Therapeutics UK Limited; and a manufacturing and supply agreement with Exemplar Pharmaceuticals, LLC. The company was founded in 2003 and is based in Mountain View, California.

About the StockGuru Leader Board:

We watch for stocks moving up and creating a positive momentum in the market.  We are not compensated for coverage.

Feel free to suggest a stock for coverage if you see it breaking out.  Contact:
IR Affiliates –
StoneBridge Web & SEO –

All content on is original content – with the exception of client news releases. All content is (C) Copyright 2002 to 2012 StockGuru. No content may be used in whole or in part without the express written consent of our Publisher. We encourage web sites interested in our content to offer a reciprocal exchange agreement in exchange for use of some of our content. We do not offer advance approval, but contact our Publisher if you have an interest in repropagating our content. Contact as at: or (469) 252-3030. Mailing address: 1601 Berwick Drive; McKinney, Texas 75070